Improvements to Test for Early Detection of Lung Cancer
Presented At International Lung Cancer Meeting


20/20 presented a new retrospective study of a multiplex immunoassay blood test that uses a panel of four tumor proteins and autoantibodies to determine the risk that non-small-cell lung carcinoma (NSCLC) is present in asymptomatic individuals from a high risk population of smokers and ex-smokers over 50. 20/20 combines protein and autoantibody tumor markers, which have been extensively studied independently of each other by several groups and are currently in clinical use for monitoring of other cancers. Data presented show that a four-biomarker panel is able to discriminate NSCLC cases from controls in a 380 retrospective sample set with 74% sensitivity, 80% specificity and 0.83 AUC, as determined by Receiver Operating Characteristic (ROC) analysis. The study confirms the value of using a combination of tumor proteins and autoantibodies for early detection of lung cancer. It is the first example of a diagnostic multiplex assay using this type of mixed panel.

“PAULA’s test is one of the few examples of a test that uses the inherent advantages of combining multiple biomarker types in a clinical assay. This test will provide greater confidence in laboratory findings for physicians evaluating individuals at risk for lung cancer and should help reduce lung cancer mortality” says meeting attendee Jeffrey A. Borgia, Assistant Professor and Facilitator, Biomedical Biomarkers Analysis Core, at Rush Medical College.

20/20’s test is already available commercially in our CLIA laboratory as PAULA’s Test (Protein Assay Utilizing Lung Cancer Analytes), Test results are now beginning to help clinicians determine which patients should be directed to appropriate diagnostic follow-up testing.

The company will continue to improve the ability of the assay to generate actionable results for clinicians. The next step will be to include additional novel biomarkers to further increase the sensitivity and specificity of the test. This project is currently in development.

About 20/20 GeneSystems, Inc.
20/20 GeneSystems, Inc. (www.2020gene.com) develops and commercializes innovative tests that aid in the early detection and therapy selection for various types of cancers. The Company is now marketing its blood test for the early detection of lung cancer through its GenesyS BioLabs business unit. 20/20 also has a patented technology for multiplex biomarker measurement in solid tumors that is being used to develop companion diagnostics for personalized medicine.

Contact:
Media & Investor Relations
Jennifer K. Zimmons, Ph.D., President
Zimmons International Communications, Inc.
(917) 214-3514
jzimmons@zimmonsic.com